Advances in ADPKD research have identified a number of promising therapeutic drugs. Several of these drugs are re-purposed compounds that are currently approved for diseases other than ADPKD. We plan to perform two pilot control trials of two of these therapeutic drugs to test the impact on ADPKD patients and to evaluate their potential.
Defining risk and personalizing treatment of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)Graham2021-09-29T16:03:21-07:00
Genetic screening and tests of kidney size can help nephrologists identify high-risk patients for new or experimental treatments, moderate-risk patients for close surveillance, and low-risk patients for reassurance. These tests, however, are costly and not widely available. We will confirm the usefulness of these tests and make them less costly, allowing for increased use in clinics.